CME examination

CME examination

To claim CME credit, complete this case-based posttest online at http://www.aad.org/JAAD/. Note: CME quizzes are available after the first of the mont...

29KB Sizes 0 Downloads 52 Views

To claim CME credit, complete this case-based posttest online at http://www.aad.org/JAAD/. Note: CME quizzes are available after the first of the month in which the article is published. A minimum score of 70% must be achieved to claim CME credit. If you have any questions, please contact the Member Resource Center of the American Academy of Dermatology at toll-free (866) 503-SKIN (7546), (847) 240-1280 (for international members), or by e-mailing [email protected].

CME examination Identification No. JB0815 August 2015 issue of the Journal of the American Academy of Dermatology.

Higgins II HW, Lee KC, Galan A, Leffell DJ. J Am Acad Dermatol 2015;73:193-203.

Directions for questions 1 and 2: Choose the single best response. A 64-year-old man presented for excision of a melanoma in situ on his back. The physical examination revealed a 1- 3 0.8-cm irregularly shaped plaque with a central biopsy scar. 1. On average, how often are melanoma in situ lesions upstaged on surgical excision? a. #10% of the time b. #20% of the time c. #30% of the time d. #40% of the time e. #50% of the time

204

A 39-year-old woman was recently diagnosed with a melanoma in situ, superficial spreading type, on the right arm. When discussing treatment options, she mentioned that her friend was also diagnosed with melanoma in situ on the face and was treated with imiquimod cream. She asked whether this would be an option for her, because she preferred not to undergo surgery. You responded that imiquimod is not the standard of therapy and is not approved by the US Food and Drug Administration for this indication. 2. Despite these issues, which of the following statements is true about imiquimod? a. There is strong evidence supporting the effectiveness of imiquimod for melanoma in situ, superficial spreading type, and this treatment would be an alternative to surgery. b. There is anecdotal evidence that imiquimod can be effective for lentigo maligna, but not for melanoma in situ, superficial spreading type. c. Imiquimod has not been shown to be effective for any type of melanoma in situ and there is minimal evidence supporting its successful use for this condition. d. Imiquimod can be effective for superficial spreading type, but the suggested treatment duration is $24 weeks. e. Imiquimod can be effective for superficial spreading type, but the suggested treatment duration is $32 weeks.